J&J lifts profit outlook on strong demand for top-seller Stelara

Stelara, J&J's top-selling anti-inflammatory drug, brought in sales of $2.86bn (€2.71bn) in the quarter.

The company's covid-19 vaccine brought in sales of $41m (€38.86m) in the quarter, compared with $489m (€463.49m) a year earlier.

Johnson & Johnson raised its 2023 profit forecast in its first earnings report since spinning off its consumer health business, with the company's fortunes now tied more closely to sales of blockbusters like its arthritis drug Stelara.

The company's shares were up about 2% in premarket trading on Tuesday.